Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

Bristol-Myers Squibb (BMS) building

BMS signs $975m deal for Bavarian Nordic cancer vaccine

Furthers prominent position in immuno-oncology with Prostvac

- PMLiVE

Sovaldi-Daklinza combo cures hep C in co-infected HIV patients

Phase III trial of BMS and Gilead antivirals cured 97% of patients

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Bristol-Myers Squibb (BMS) building

BMS buys immunotherapy specialist Flexus in $1.2bn deal

And signs new cancer research partnership with Rigel

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

- PMLiVE

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  

- PMLiVE

BMS names Giovanni Caforia as new CEO

Current chief operating officer will succeed Lamberto Andreotti in May

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo set for early access in UK

First anti-PD1 to be given fast-track status in the country

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

Bristol-Myers Squibb (BMS) building

Opdivo to be tested as ‘double immunotherapy’ for tumours

BMS and Ono to test anti-PD-1 in combination with Kyowa Hakko's mogamulizumab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links